Impact News +++ Village Farms International Creates Global Strategy Officer Role and Appoints Brian Stevenson (GlobeNewswire EN) +++ VILLAGE FARMS Aktie -3,74%

IMMURON ADR Aktie

>IMMURON ADR Aktienkurs

0.803 EUR (Tradegate)

Ask: 0.83 EUR / 1204 Stück

Bid: 0.775 EUR / 1290 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

IMMURON ADR Aktie über LYNX handeln

Intraday

1 Jahr

>IMMURON ADR Performance

1 Woche: -37,9%

1 Monat: -39,7%

3 Monate: -48,2%

6 Monate: -47,2%

1 Jahr: -60,6%

laufendes Jahr: -57,0%

>IMMURON ADR Aktie

Name:

IMMURON LTD SPON.ADR 40

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US45254U1016 / A2DTD8

Symbol/ Ticker:

ANWA (Frankfurt) / IMRN (NASDAQ)

Kürzel:

FRA:ANWA, ETR:ANWA, ANWA:GR, NASDAQ:IMRN

Index:

Webseite:

https://www.immuron.com.a..

Profil:

Immuron Ltd Sponsored ADR represents a foreign ent..
>Volltext..

Marktkapitalisierung:

7.38 Mio. EUR

Unternehmenswert:

4.1 Mio. EUR

Umsatz:

4.03 Mio. EUR

EBITDA:

Nettogewinn:

-2.88 Mio. EUR

Gewinn je Aktie:

-0.5 EUR

Schulden:

Liquide Mittel:

1.58 Mio. EUR

Operativer Cashflow:

-3.25 Mio. EUR

Bargeldquote:

2.98

Umsatzwachstum:

47.17%

Gewinnwachstum:

25.88%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

IMMURON ADR, IMMURON

Letzte Datenerhebung:

17.12.25

>IMMURON ADR Kennzahlen

Aktien/ Unternehmen:

Aktien: 8.17 Mio. St.

Frei handelbar: -

Leerverk. Aktien: 1.19%

Rückkaufquote: -2%

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 315.76%

Bewertung:

KGV: -

KGV lG: -

KUV: 1.2

KBV: 1.06

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 65.42%

Gewinnmarge: -71.37%

Operative Marge: -92.59%

Managementeffizenz:

Gesamtkaprendite: -39.65%

Eigenkaprendite: -49%

>IMMURON ADR Peer Group

Es sind 599 Aktien bekannt.

>IMMURON ADR Chart & Kurs - NASDAQ

>IMMURON ADR News

10.12.25 - 15:30	Immuron-Aktie bricht ein: Klinische Studie verfehlt primären Endpunkt (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.12.25 - 12:03	Immuron New U.S. Department of Defense Award & Clinical Trial Update (GlobeNewswire EN)
	Highlights:...

05.11.25 - 12:03	Immuron IMM-529 IND approved by FDA (GlobeNewswire EN)
	Key Points...

31.10.25 - 14:42	Immuron reports delay in Travelan study data (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.10.25 - 11:03	Immuron Announces Clinical Trial Update (GlobeNewswire EN)
	MELBOURNE, Australia, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company provides a clinical trial update on Travelan® and IMM-529....

17.10.25 - 17:24	Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target (Newsfile)
	New York, New York--(Newsfile Corp. - October 17, 2025) - Emerging Growth Research today announced the initiation of coverage on Immuron Limited (Nasdaq: IMRN) with a Buy-Extended rating and a 12-......

13.10.25 - 12:03	Immuron Q1 FY26 YoY growth (GlobeNewswire EN)
	Sales Highlights (unaudited):...

08.10.25 - 12:03	Immuron Submits IMM-529 IND to FDA (GlobeNewswire EN)
	Key Points...

02.10.25 - 12:03	Immuron Letter to Shareholders – Projects Update (GlobeNewswire EN)
	Highlights:...

27.08.25 - 04:33	Immuron partners with InvestorHub (GlobeNewswire EN)
	MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors....

17.07.25 - 12:03	Immuron - FY25 global sales exceed projection, up 49% on prior year (GlobeNewswire EN)
	Sales Highlights (unaudited):...

30.05.25 - 12:03	Immuron Letter to Shareholders: Projects Update (GlobeNewswire EN)
	Highlights:...

11.04.25 - 09:39	Immuron exceeds AUD$5 million in sales in a fiscal year (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.04.25 - 00:03	Immuron Travelan® highest sales in history (GlobeNewswire EN)
	Sales Highlights (unaudited):...

05.03.25 - 12:03

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) (GlobeNewswire EN)

MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will join Immuron's product portfolio which includes the rapidly growing Travelan® brand building on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will love to recommend....

17.01.25 - 12:03	Immuron Travelan® continued strong sales growth (GlobeNewswire EN)
	Sales Highlights:...

15.01.25 - 12:03	Immuron Announces New Research Collaboration targeting Antimicrobial Resistance (GlobeNewswire EN)
	Highlights:...

14.01.25 - 12:03	Immuron Announces Travelan® Clinical Trial Update (GlobeNewswire EN)
	Highlights:...

14.01.25 - 06:01	Immuron progresses development of traveller’s diarrhea drug Travelan (Market Herald)
	Immuron Ltd (ASX:IMC) has moved through a series of development milestones for…...

02.12.24 - 12:03	Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th (GlobeNewswire EN)
	MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com on Thursday 5th December 2024 (2.30pm U.S. Eastern time)....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram